Pramipexole prolonged release tablets (Mirapexin®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000388
English
Authors' recommendations:
Pramipexole prolonged release (Mirapexin prolonged release®) is recommended as an option for use within NHS Wales for the treatment of the signs and symptoms of idiopathic Parkinson's disease, alone or in combination with levodopa.
Pramipexole prolonged release should be initiated by a specialist experienced in the treatment of Parkinson's disease. AWMSG is of the opinion that pramipexole prolonged release may be suitable for shared care in accordance with appropriate local guidance.
In order to limit potential errors, pramipexole prolonged release should be prescribed by brand as Mirapexin prolonged release®.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=158221&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Parkinson Disease
- Antiparkinson Agents
- Delayed-Action Preparations
- Benzothiazoles
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.